June 1, 2012
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative DirectorPresident and Chief Executive Officer

SYMBIO ANNOUNCES DATA PRESENTATIONS AT 48th ANNUAL AMERICAN SOCIETY OF
CLINICAL ONOCLOGY MEETINGTOKYO, Japan, June 1, 2012 – SymBio Pharmaceuticals Limited (JASDAQ: 4582) announced todaythat it will present data highlighting new study results related to bendamustine hydrochloride(TREAKISYM®) and oral rigosertib during the 48th Annual Meeting of the American Society of ClinicalOncology (ASCO), taking place in Chicago from June 1 to June 5, 2012.
Nine abstracts will be presented for bendamustine hydrochloride (TREAKISYM®), including resultsfrom the Japanese and Korean Lymphoma cooperative group-sponsored Phase 2 study for thetreatment of refractory and relapsed aggressive non-Hodgkin’s lymphoma in Japan. The results of thisPhase 2 trial will be presented in an oral discussion by Dr. Michinori Ogura (Nagoya, Daini Red CrossHospital) on June 2, 2012 from 12:00pm to 1:00pm in room E354a.
In partnership with Eisai Co., Ltd., SymBio received Japanese marketing approval of TREAKISYM®
(SyB L-0501) in October, 2010, for the treatment of patients with refractory/relapsed low-grade nonHodgkin’s lymphoma and mantle cell lymphoma. SymBio has also initiated Phase 2 trials for SyB L0501 in frontline low-grade non-Hodgkin’s lymphoma, mantle cell lymphoma, and refractory/relapsed
multiple myeloma patients.
ASCO 2012 BENDAMUSTINE (TREAKISYM®) ABSTRACTS:#Abstract
Abstract Name
Number1 3
Bendamustine plus rituximab (B-R) versus CHOP plus rituximab(CHOP-R) as first-line treatment in patients with indolent andmantle cell lymphomas (MCL): Updated results from the StiL NHL1study.
http://abstract.asco.org/AbstView_114_95807.html
Plenary session: Sunday June 3, 1:00pm to 4:00pm in N Hall B1
2 6515
Combination of the Bruton's tyrosine kinase (BTK) inhibitor PCI32765 with bendamustine (B)/rituximab (R) (BR) in patients (pts)with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL):
Interim results of a phase Ib/IIstudy.
http://abstract.asco.org/AbstView_114_98278.html
Poster discussion session: June 1, 1:00pm to 5:00pm in S405
Discussion time: Friday June 1, 4:30pm to 5:30pm in S406
3 6553Cost-effectiveness analysis of bendamustine plus rituximab versus
CHOP-R in treatment-naive patients with mantle cell (MCL) andindolent lymphomas (IL).
http://abstract.asco.org/AbstView_114_90712.html
Poster viewing: Monday June 4, 1:15pm to 5:15pm in S Hall A2
4 6566
Bendamustine retreatment of CLL in the outpatient setting.
http://abstract.asco.org/AbstView_114_96159.html
General poster session: Monday June 4, 1:15pm to 5:15pm in S

57094

68014

78023

88026

99547

Hall A2
A phase II study of second-line bendamustine in relapsed orrefractory small cell lung cancer (SCLC).
http://abstract.asco.org/AbstView_114_96985.html
Poster viewing: Saturday June 2, 1:15pm to 5:15pm in S Hall A2
Bendamustine, bortezomib, and dexamethasone (BVD) in elderly
patients with relapsed/refractory multiple myeloma (RRMM): The
Intergroupe Francophone du Myélome (IFM) 2009-01 protocol.
http://abstract.asco.org/AbstView_114_93400.html
Oral abstract session: Sunday June 3, 8:00am to 11:00am in E354a
A multicenter phase II study of bendamustine with rituximab inpatients with relapsed/refractory diffuse large B-cell lymphoma(DLBCL) (SymBio-Sponsored Study)
http://abstract.asco.org/AbstView_114_96015.html
Poster viewing: Saturday June 2, 8:00am to 12:00pm in E450b
Poster discussion: Saturday June 2, 12:00pm to 1:00pm in E354a
Multicenter, phase II study of bendamustine in refractory or
relapsed T-cell lymphoma: The BENTLY trial.
http://abstract.asco.org/AbstView_114_97842.html
Poster discussion session: Saturday June 2, 8:00am to 12:00pm inE450b
Discussion time: Saturday June 2, 12:00pm to 1:00pm in E354a
Pharmacokinetics (PK) of bendamustine in pediatric patients withrelapsed/refractory acute leukemia.
http://abstract.asco.org/AbstView_114_97053.html
Poster viewing: Sunday June 3, 8:00am to 12:00pm at S Hall A2

In addition to TREAKISYM-related abstracts, two abstracts on rigosertib trials, sponsored by Onconova
Therapeutics, Inc. have been accepted for presentation.
In Japan, SymBio received clinical trial approval for a Phase 1 study of rigosertib in relapsed/refractory
myelodysplastic syndrome (MDS) patients. SymBio is also planning to initiate a Phase I clinical trial forthe treatment of frontline MDS using the oral form of rigosertib based on promising results generated inU.S. Phase 2 clinical trials.
ASCO 2012 RIGOSERTIB ABSTRACTS#Abstract
Abstract Name
Number1 3017
Phase I study of oral rigosertib in patients with advanced solidtumors. (Sponsored by Onconova, SymBio’s partner)
http://abstract.asco.org/AbstView_114_98060.html
Poster discussion session: Saturday June 2, 1:15pm to 5:15pm inS405
Discussion time: Saturday June 2, 4:45pm to 5:45pm in S406
2 3081
A phase I study to assess oral bioavailability of a novel oral soft
gelatin capsule formulation of rigosertib (ON 01910.Na) underfasted and fed conditions in patients with myelodysplastic
syndromes. (Sponsored by Onconova, SymBio’s partner)http://abstract.asco.org/AbstView_114_96744.html
Poster viewing: Monday June 4, 8:00am to 12:00pm in S Hall A2[Contact]
Hiroki Maekawa
Board Director, Corporate Officer, Chief Financial Officer
Tel: +081(0)3 5472 1125